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ABSTRACT

Prior to Janus kinase inhibitors, available therapies for myelofibrosis w ere generally supportive and did not
improve survival. This analysis compares efficacy outcomes of patients w ith myelofibrosis in the control arms
(placebo [n=154] and best available therapy [n=73]) from the tw o phase 3 CO ntrolled MyeloFibrosis study w ith
O Ral JAK inhibitor Treatment (CO MFO RT) studies. Spleen volume w as assessed by magnetic resonance imaging/computed tomography at baseline and every 12 w eeks through w eek 72; spleen length w as assessed by palpation at each study visit. Health-related quality of life and symptoms w ere assessed using the European
O rganisation for Research and Treatment of Cancer Q uality of Life Q uestionnaire-Core 30 Items at baseline and
in w eeks 4, 8, 12, 16 and 24 in CO MFO RT-I and in w eeks 8, 16, 24 and 48 in CO MFO RT-II. The demographic
and baseline characteristics w ere similar betw een the control arms of the tw o studies. One patient w ho received
placebo and no patients w ho received best available therapy had a ≥35% reduction in spleen volume from baseline
at w eek 24. At 24 w eeks, neither placebo nor best available therapy had produced clinically meaningful changes
in global quality of life or symptom scales. Non-hematologic adverse events w ere mostly grade 1/2; the most frequently reported adverse events in each group w ere abdominal pain, fatigue, peripheral edema and diarrhea.
These data suggest that non–Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared w ith placebo. Both COMFO RT-I (NCT00952289) and CO MFO RT-II
(NCT00934544) studies have been appropriately registered w ith clinicaltrials.gov.

Introduction
Myelofibrosis has the w orst median overall survival of the
BCR-ABL–negative myeloproliferative neoplasms and can
present as primary disease or evolve from polycythemia vera
or essential thrombocythemia.1 Regardless of its origin,
myelofibrosis is characterized by bone marrow fibrosis, progressive splenomegaly, cytopenias and burdensome debilitating constitutional symptoms,2 leading to a severely diminished quality of life (Q oL).3 The median survival of patients
w ith myelofibrosis ranges from 2 to 11 years, depending on
defined prognostic factors.4
Treatment options for myelofibrosis have generally been

palliative w ithout impact on the natural history of the disease. Although stem cell transplant is a potentially curative
treatment for patients w ith myelofibrosis, it is an option for
only a minority of patients, and the rates of mortality and
treatment-related toxicities and complications remain high.5
How ever, the recent identification of aberrant activation of
the Janus kinase (JAK) signaling pathw ay – along w ith an
improved understanding that cytokines that signal through
JAK1 and JAK2 play a role in the development of myeloproliferative neoplasms – has led to the development of new
therapeutic approaches.6-9
Ruxolitinib (also know n as INC424 and INCB018424) is a
potent and selective inhibitor of JAK1 and JAK2. It w as
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approved in November 2011 by the US Food and Drug
Administration for the treatment of intermediate- or highrisk myelofibrosis10 and more recently by Health Canada 11
and the European Commission for the treatment of
m yelofibrosis-related splenom egaly or sym ptom s.12
Ruxolitinib w as approved based on data from tw o pivotal
phase 3 CO ntrolled MyeloFibrosis study w ith O Ral JAK
inhibitor Treatment (CO MFO RT) trials:13,14 CO MFO RT-I
w as double-blind and placebo-controlled and CO MFO RTII w as an open-label study that compared ruxolitinib w ith
best available therapy (BAT). In both studies, patients w ho
received ruxolitinib had rapid and durable reductions in
splenomegaly and improvements in disease-related symptoms, role functioning and Q oL measures. In contrast,
patients in the control arms of both of these studies generally had increases in splenomegaly and w orsening of
symptoms, demonstrating that non–JAK inhibitor treatments w ere not efficacious. Here, w e present a post hoc
analysis specifically evaluating the efficacy outcomes and
safety of the placebo arm of CO MFO RT-I compared w ith
those of the BAT arm of CO MFO RT-II.

Methods
Patients, study design and treatment
CO MFO RT-I w as a randomized (1:1), double-blind,
multicenter study that compared the safety and efficacy of
ruxolitinib 15 or 20 mg tw ice daily (n=155) w ith placebo
(n=154) in patients w ith primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.13 CO MFO RT-II w as a randomized (2:1), open-label, multicenter study that compared
ruxolitinib 15 or 20 mg tw ice daily (n=146) w ith BAT
(n=73) in patients w ith patients w ith primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.14 The choice of dose
of ruxolitinib (15 or 20 mg tw ice daily) w as based on
platelet count at baseline (100-200 or >200x109/L, respectively). Eligibility criteria w ere previously reported elsew here.13,14 BAT included any com mercially available
agents (as monotherapy or in combination) or no therapy
at all and could be changed during the treatment phase
(Table 1).14 Crossover w as permitted in each study according to the protocol-specified criteria previously
described.13,14 The CO MFO RT-I and CO MFO RT-II studies
w ere approved by the institutional review boards of the
respective institutions and conducted in accordance w ith
the principles of the Declaration of Helsinki. All patients
provided w ritten informed consent.

Assessments
As previously described, the analysis for this study w as
conducted w hen all enrolled patients completed w eek 24
for CO MFO RT-I (data cut-off date, November 2, 2010)13
or w eek 48 for CO MFO RT-II (data cut-off date, January 4,
2011)14 or w ere w ithdraw n from the study. The primary
end-point w as a reduction of ≥35% in spleen volume from
baseline at w eek 24 and w eek 48 for CO MFO RT-I and
CO MFO RT-II, respectively. CO MFO RT-II had a key secondary end-point (type I error controlled) of reduction of
≥35% in spleen volume from baseline at w eek 24. Spleen
volume w as assessed by magnetic resonance imaging
(MRI) or computed tomography (CT; in those patients
w ho w ere not candidates for MRI) every 12 w eeks up to
ha e ma tologica | 2014; 99(2)

w eek 72. In CO MFO RT-I, any patient w ho crossed over
before w eek 24 or discontinued from the study w as counted as a non-responder for response measures of reduction
in spleen volume and symptom improvement. In CO MFO RT-II, any patient w ho discontinued from the study or
had a protocol-defined event of disease progression 14
before w eek 48 w as considered to be a non-responder.
Spleen length w as assessed by manual palpation at every
study visit.
Health-related Q oL and symptoms w ere assessed using
the European O rganisation for Research and Treatment of
Cancer Q uality of Life Q uestionnaire-Core 30 Items
(EO RTC Q LQ -C30), w hich w as completed by patients at
baseline in both studies, in w eeks 4, 8, 12, 16 and 24 in
CO MFO RT-I and in w eeks 8, 16, 24 and 48 in CO MFO RT-II. The EO RTC Q LQ -C30 includes five functional
scales (physical, role, emotional, cognitive and social functioning), a global health status/Q oL scale and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnea,
insomnia, appetite loss, constipation, diarrhea and financial difficulties). All scores range from 0 to 100. For functional and global health status/Q oL scales, higher scores
indicate better Q oL; for symptom scales, higher scores
indicate more severe symptoms. For the EO RTC Q LQ C30 global health status/Q oL scale, patients w ith a 10%
(or 10-point) improvement in score w ere considered to
have clinically meaningful improvements.15

Res ults
In the CO MFO RT-I and CO MFO RT-II studies, 154
patients received placebo and 73 patients received BAT,
respectively, and all w ere included in the primary efficacy
analyses except for one patient in each group w ith a missing baseline spleen volume assessment. Among those w ho
w ere randomized to BAT, 49 patients (67% ) received any
BAT medication – referred to hereafter as BAT-treated –
and 24 patients (33% ) received no therapy as BAT during
the randomized treatment phase. As previously described
by Harrison et al.,14 of the 49 BAT-treated patients, 37
patients (76% ) w ere given antineoplastic agents, most
commonly hydroxyurea (n=32; 65% ), and 12 patients
(24% ) w ere given glucocorticoids. The demographic and
baseline characteristics w ere generally similar betw een
the control arms of the tw o studies (Table 2), including
Table 1. Patients’ treatments on the BAT-treated arm.14

Agent
Antineoplastic agents
Hydroxyurea
Glucocorticoids
Epoetin alfa
Immunomodulators
Purine analogues
Androgens
Interferons
Nitrogen mustard analogues
Pyrimidine analogues

BAT, n. (%)
(n=73)
37(51)
34(47)
12(16)
5(7)
5(7)
4(5)
3(4)
3(4)
2(3)
2(3)

BAT: best available therapy.
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spleen length below the costal margin: median, 16.0 cm
(range, 5.0-34.0) and 15.0 cm (range, 5.0-37.0) in the placebo and BAT arms, respectively. Compared w ith patients
w ho received BAT, those w ho received placebo w ere
older and higher proportions had high-risk disease and
w ere JAK2 V617F-positive and hydroxyurea-naïve.
O verall, 52% of patients receiving placebo and 42% of
patients receiving BAT (35% BAT-treated) w ere ongoing
in the randomized treatment phase at the data cut-off date
(Table 3). O f those w ho discontinued the study, a similar
proportion of patients in each group crossed over to
receive ruxolitinib [placebo, 36 of 151 (24% ); BAT, 18 of
73 (25% ; of w hom 12 of 18 (67% ) w ere BAT-treated)].

Efficacy
Spleen size
As show n in Figure 1, only one patient (0.7% ) w ho
received placebo and no patients w ho received BAT
achieved a ≥35% reduction in spleen volume from baseline at w eek 24 (the primary end-point of CO MFO RT-I
and the key secondary end-point of CO MFO RT-II). The
patient in the placebo arm w ho achieved this reduction in
spleen volume died from disease progression 4 days later,
possibly from splenic infarction.16 During the 24-w eek
period, the majority of patients treated w ith placebo
(75% ) or BAT (69% ) had measurable increases in spleen
volume. O f those patients in the BAT group, a similar pro-

60
40

Change from baseline, %

20
0
-20
35% decrease

-40
Placebo (n=106)

-60

BAT (n=45)
BAT treated (n=26)
BAT untreated (n=19)

-80

Figure 1. Percent change from baseline in
spleen volume as assessed by magnetic resonance imaging/ computed tomography at
week 24 for patients with baseline and ≥1
post-baseline assessment. BAT: best available therapy.

-100
Table 2. Patients’ demographic and baseline characteristics.

COMFORT-I
Placebo
(n=154)
Age, median (range), year
70(40-86)
Male, n. (%)
88(57)
Myelofibrosis type, n. (%)
PMF
84(55)
PPV-MF
47(31)
PET-MF
22(14)
High/intermediate-2
99(64)/54(35)
IPSSrisk, n. (%)
JAK2V617Fpositive, n. (%)
123(80)
Palpable spleen size
16.0(5.0-34.0)
belowcostal margin, median
(range), cm
Spleen volume,* median
2566.3
(521.0-8880.7)
(range), cm3
Prior HUtherapy, n. (%)
87(56)

Table 3. Patients’ disposition.

COMFORT-II
BAT
BATtreated
(n=73)
(n=49)
66(35-85)
42(58)

67(46-85)
29(59)

39(53)
20(27)
14(19)
43(59)/29(40)

25(51)
16(33)
8(16)
28(57)/21(43)

49(67)
15.0(5.0-37.0)

36(73)
16.5(6.0-37.0)

2317.9
(728.5-7701.1)
50(68)

2482
(728.5-7701.1)
43(88)

Patients, n. (%)

COMFORT-I
Placebo
(n=151)*

Ongoingin randomized
treatment phase
Crossed over to ruxolitinib**
Discontinued
Disease progression
Death
Adverse event(s)
Consent withdrawn
Other
Non-compliance with studyprocedure

COMFORT-II
BAT
BATtreated
(n=73)
(n=49)

78(52)

31(42)

17(35)

36(24)
37(25)
12(8)
9(6)
8(5)
5(3)
3(2)
0

18(25)
24(33)
3(4)
0***
4(5)
9(12)
7(10)****
1(1)

12(24)
20(41)
3(6)
0***
4(8)
7(14)
5(10)
1(2)

COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available
therapy. * The other three patients were not evaluable for safety but were included in the intentionto-treat analysis of efficacy. * * According to protocol-defined criteria for crossover. * * * Deaths were
not reported as a reason for discontinuation in COMFORT-II. However, there were four deaths in
the BAT group; all four patients were BAT-treated and were counted in different reasons for discontinuation. * * * * Included investigator decision, splenectomy, treatment failure, poor patient condition, refusal of follow-up, bone marrow transplant and thrombocytopenic event confirming disease
progression (1 each).

COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available
therapy; PMF: primary myelofibrosis; PPV-MF: post–polycythemia vera myelofibrosis; PET-MF:
post–essential thrombocythemia myelofibrosis; IPSS: International Prognostic Scoring System;
JAK2: Janus kinase 2; HU: hydroxyurea. * Normal spleen volume is 150 to 200 cm3.
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portion of BAT-treated patients [18 of 26 (69% )] and of
those w ho received no BAT medications (13 of 19 [68% ])
had spleen volume increases.
The mean percentage change in spleen volume over
time increased in the control groups of both studies and,
in general, these increases w ere observed by the first
assessment (12 w eeks; Figure 2A). Changes in palpable
spleen length in both groups mirrored the increases in
spleen volume assessed by MRI/CT (Figure 2B). Although
treatment in the BAT group w as not blinded to the
patients, all scans w ere read by a central blinded reader
and, in general, sim ilar increases in spleen volum e
assessed by MRI/CT w ere observed betw een the overall
BAT and BAT-treated groups over time. With palpable
spleen length, in w hich measurements w ere not blinded,
some differences in the mean percentage change in spleen
length over time betw een the BAT-treated and overall BAT
populations w ere observed, w ith an apparent tendency
tow ard smaller changes.

group had a clinically meaningful improvement in global
health status/Q oL. Patients in each of the control groups
had w orsening from baseline in role functioning, w hich
w as clinically significant for the placebo group at w eek 24.
Additionally, regardless of the control group, patients generally had w orsening of myelofibrosis-associated symptoms, including appetite loss, dyspnea, insomnia and pain.
In particular, w orsening of appetite loss and dyspnea w as
observed in BAT-treated patients, and w orsening of pain
w as noted in placebo patients. Although scores for insomnia show ed some improvements w ith placebo and scores
for pain and fatigue show ed improvements in BAT-treated
patients, no clinically meaningful improvements w ere
observed in either group.

Safety
As show n in Table 4, patients w ho received placebo generally reported higher rates of the most frequent non-hematologic adverse events. Events that occurred w ith approximately ≥10% higher incidence in the placebo arm than in
the BAT arm w ere abdominal pain (41% w ith placebo versus14% w ith BAT), fatigue (34% versus8% ), diarrhea (21%
versus 12% ) and nausea (19% versus 7% ). Peripheral edema
w as the most frequently reported adverse event in the BAT
group (26% ) and w as also reported at a similar rate in the

Symptoms and other patient-reported outcomes
At w eek 24, patients in the placebo arm and BAT arms
did not have clinically meaningful improvements from
baseline in any of the health-related Q oL (Figure 3) or
symptom scores (Figure 4), w hereas the BAT-treated sub-

A

B

0

12

24
Weeks

36

48

n=154
n=72
n=49

132
60
38

106
45
26

46
40
22

13
34
20

Placebo

Mean change from baseline

15
10

Clinically significant

-5

BAT

20
15
10
5
0
-5
-10
-15
-20

12

n=154 147 141 136 123
n=72 63 56 50 49
n=49 47 37 32 27

n=

104

37

11.1

23

105

39

-3.4

23

-3.6
-6
-11

Global health status/QoL
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BAT treated

24
Weeks

36

48

108
41
24

44
30
17

14
31
16

Figure 2. Mean percentage change from
baseline in (A) spleen
volume as assessed by
magnetic resonance
i m agi ng/ com put ed
tomography and (B)
palpable spleen length
over time. BAT: best
available therapy.

BAT treated

-10
-15

0

BAT

5.2

5
0

Placebo

BAT treated

Role functioning

Improvement

BAT

Worsening

Placebo
20
15
10
5
0
-5
-10
-15
-20

Figure 3. Mean change from baseline
to week 24 in European Organisation
for Research and Treatment of
Cancer (EORTC) Quality of Life (QoL)
Questionnaire-Core 30 Items (QLQC30) scores. Only patients with measurements at both baseline and week
24 were included. EORTC QLQ-C30
global health status/ QoL and functioning scales range from 0 to 100,
with higher scores indicating better
health-related QoL. A clinically meaningful treatment difference was
defined as a 10-point improvement or
10-point worsening from baseline for
global health status/ QoL. BAT: best
available therapy.
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placebo group (23% ). There w ere no events that occurred
w ith a ≥10% higher incidence in the BAT arm than in the
placebo arm; cough and nasopharyngitis w ere reported at a
≥5% higher incidence in patients w ho received BAT compared w ith those w ho received placebo. When BAT-treated
patients w ere considered, peripheral edema, cough and
asthenia w ere reported at a ≥5% higher rate than in patients
w ho received placebo. In general, the rates of grade 3/4
adverse events w ere similar betw een the control arms,
although rates of abdominal pain (11% w ith placebo versus
3% w ith BAT) and fatigue (7% versus 0% ) w ere higher in
the placebo arm than in the BAT arm. Of the most common

Placebo (n= 107)
BAT (n= 39)
BAT treated (n= 23)

grade 3/4 events reported in the BAT arm of COMFORT-II,
all but one (a case of dyspnea) occurred in BAT-treated
patients.

Discus s ion
More than 130 years after the first description of
myelofibrosis by Heuck in 1879,17 the treatment of
patients w ith this condition has remained mostly supportive and the natural progression of myelofibrosis has not
been significantly improved by drug therapy.18 In both of

10.1

0.9
0.6
5.8
6

Appetite loss

Insomnia

-2.2*
10.1
5.3* *

Dyspnea

1*
-2.2

3

Pain
8.3* * *

-4.1
-1

-20

-15

-10

Fatigue

1.8

-5
0
5
Mean change from baseline

10

15

20

Figure 4. Mean change from baseline
to week 24 in select European
Organisation for Research and
Treatment of Cancer (EORTC) Quality of
Life (QoL) Questionnaire Core 30 Items
(QLQ-C30) scores. EORTC QLQ-C30
symptom scales range from 0 to 100,
with higher scores indicating worse
symptoms. BAT: best available therapy.
* n=105. * * n=38. * * * n=104.

Table 4. Non-hematologic adverse events regardless of study drug relationship (≥10% in any group).

Adverse event
Abdominal pain
Fatigue
Peripheral edema
Diarrhea
Nausea
Dyspnea
Cough
Pruritus
Nasopharyngitis
Constipation
Night sweats
Back pain
Asthenia
Insomnia
Pain in extremity
Pyrexia
Vomiting

COMFORT-I
Placebo (n=151)*
All grades, n. (%)
Grade3/ 4, n. (%)
62(41)
51(34)
34(23)
32(21)
29(19)
26(17)
13(9)
23(15)
9(6)
18(12)
18(12)
12(8)
12(8)
15(10)
15(10)
11(7)
15(10)

17(11)
10(7)
2(1)
0
1(1)
6(4)
0
2(1)
0
0
2(1)
1(1)
4(3)
0
0
1(1)
1(1)

COMFORT-II
BAT(n=73)**
BATtreated (n=49)**
All grades, n. (%) Grade 3/ 4, n. (%)
All grades, n. (%) Grade 3/ 4, n. (%)
10(14)
6(8)
19(26)
9(12)
5(7)
13(18)
11(15)
9(12)
10(14)
4(5)
6(8)
8(11)
7(10)
5(7)
3(4)
7(10)
1(1)

2(3)
0
0
0
0
3(4)
1(1)
0
0
0
0
0
1(1)
0
0
0
0

6(12)
4(8)
14(29)
6(12)
5(10)
8(16)
7(14)
5(10)
5(10)
3(6)
3(6)
4(8)
7(14)
4(8)
3(6)
4(8)
1(2)

2(4)
0
0
0
0
2(4)
1(2)
0
0
0
0
0
1(2)
0
0
0
0

COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available therapy.* Median 32.2 weeks of follow-up.* * Median 50.1 weeks of follow-up.
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the CO MFO RT studies, it w as demonstrated that significantly more patients w ho received ruxolitinib had rapid
and durable reductions in splenom egaly as w ell as
improvements in symptoms and Q oL compared w ith
patients in the control arms, and that these reductions
w ere maintained throughout each study period.13,14 The
lack of efficacy w ith non–JAK inhibitor therapeutics in
CO MFO RT-II is of the utmost relevance because conclusions from previous studies of therapeutics in patients
w ith myelofibrosis have been hampered by small numbers and the lack of objective response criteria and a control arm.19-22 For example, one retrospective study show ed
that the use of hydroxyurea, w hich w as the most common treatment in the BAT arm, resulted in a 40% rate of
clinical improvement by International Working GroupMyeloproliferative Neoplasms Research and Treatment
(IWG-MRT) criteria, w ith improvements in splenomegaly,
symptoms and blood counts.20 How ever, this study only
included 40 patients, and the subgroups evaluated w ere
small, w ith 18 patients evaluable for spleen size and 22
patients evaluable for constitutional symptoms; in addition, the lack of a control arm makes the reported response
rates difficult to interpret.
We acknow ledge that a direct side-by-side comparison
w ould be ideal to assess the efficacy of BAT compared
w ith placebo and recognize that the data presented here
are inevitably limited because they are derived from tw o
different studies. How ever, although there are some differences in the patient populations and eligibility and
inclusion criteria of the CO MFO RT-I and CO MFO RT-II
studies, the general similarities in the trial end-points, period of accrual and responses achieved w ith ruxolitinib in
each of the studies allow for some meaningful comparisons. In this post hoc analysis, patients w ho received BAT
had numerically similar increases in spleen size as those
w ho received placebo, and no clinically meaningful
improvements in Q oL or symptoms w ere seen in either
the placebo or BAT arm. These data suggest that non–JAK
inhibitor treatm ents for m yelofibrosis provide little
improvement in spleen size, symptoms or health-related
Q oL compared w ith placebo. Although it is conceivable
that some patients in the BAT arm of CO MFO RT-II w ere
not sufficiently aggressively treated, this is unlikely as evidenced by the observation that some patients had spleen
regression and that anemia and transfusion rates w ere
equivalent across the tw o arms of CO MFO RT-II.
Whereas CO MFO RT-I w as a double-blind, placebocontrolled study, CO MFO RT-II w as an open-label study
in w hich treatment in the BAT arm w as based on physicians’ choice and could, therefore, include any single treatm ent or com bination of treatm ents, including any
sequence of treatments or no treatment (i.e. “w atchful
w aiting”). Based on these options, approximately onethird of the patients in the BAT arm received no
treatment.14 To account for this possible confounding factor, the efficacy and safety data of the 49 patients (67% )
w ho received any BAT medication w ere evaluated as a
separate subgroup. A similarly low proportion of patients
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